Korean J Hematol 1994; 29(1):
Published online March 31, 1994
© The Korean Society of Hematology
재생불량성 빈혈에 있어서 면역조절요법
김형준, 서재성, 박상선, 박경옥, 국훈, 황태주
전남대학교 의과대학 내과학교실,
전남대학교 의과대학 소아과학교실
Immunomodulative Therapy for Aplastic Anemia Patients
Background and Methods:Immunosuppression has known to be the best treatment option for patients with aplastic anemia who are not candidate for bone marrow transplantation. The best results are reported by the use of antilympocyte globulin(ALG) with or without cyclosporine.
We performed a therapeutic trial in 20 patients not eligible for bone marrow transplantation, with ALG and cyclosporine.
Results: The results of the regimen including cyclosporine were 40% response rates at six months. All responding patients at 16 months are still alive. ALG and cyclosporine
had substantial but reversible side effects.
Conclusion: Immunosuppressive treatment of aplastic anemia with ALG and cyclosporine appears to be effective and may thus be represent a treatment of choice for patients who are not eligible for bone marrow transplantation.
Keywords Aplastic anemia; ALG; Cyclosporine;
PDF
Standard view
Export citation
Share Article
Korean J Hematol 1994; 29(1): 15-21
Published online March 31, 1994
Copyright © The Korean Society of Hematology.
재생불량성 빈혈에 있어서 면역조절요법
김형준, 서재성, 박상선, 박경옥, 국훈, 황태주
전남대학교 의과대학 내과학교실,
전남대학교 의과대학 소아과학교실
Immunomodulative Therapy for Aplastic Anemia Patients
Hyung Jun Kim, Jae Sung Seo, Sang Sun Park, Kyung Ok Park, Hoon Kook, Tae Joo Hwang
Department of Internal Medicine, Pediatrics, Chonnam National University Hospital, Kwangju, Korea
Abstract
Background and Methods:Immunosuppression has known to be the best treatment option for patients with aplastic anemia who are not candidate for bone marrow transplantation. The best results are reported by the use of antilympocyte globulin(ALG) with or without cyclosporine.
We performed a therapeutic trial in 20 patients not eligible for bone marrow transplantation, with ALG and cyclosporine.
Results: The results of the regimen including cyclosporine were 40% response rates at six months. All responding patients at 16 months are still alive. ALG and cyclosporine
had substantial but reversible side effects.
Conclusion: Immunosuppressive treatment of aplastic anemia with ALG and cyclosporine appears to be effective and may thus be represent a treatment of choice for patients who are not eligible for bone marrow transplantation.
Keywords: Aplastic anemia, ALG, Cyclosporine,
Previous Article
